(Q37798817)

23 August 2017

title

Developing better treatments in hepatocellular carcinoma (English)

1 reference

23 August 2017

Austin Duffy

1

1 reference

23 August 2017

Tim Greten

series ordinal

2

1 reference

23 August 2017

publication date

1 October 2010

1 reference

Expert Review of Gastroenterology & Hepatology

23 August 2017

published in

1 reference

23 August 2017

volume

4

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

551-560

1 reference

Estimating the world cancer burden: Globocan 2000.

23 August 2017

cites work

1 reference

Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort

21 January 2018

1 reference

Prospective validation of the Barcelona Clinic Liver Cancer staging system

21 January 2018

1 reference

Advanced hepatocellular carcinoma: which staging systems best predict prognosis?

21 January 2018

1 reference

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

21 January 2018

1 reference

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.

21 January 2018

1 reference

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

21 January 2018

1 reference

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study.

21 January 2018

1 reference

Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma

21 January 2018

1 reference

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

21 January 2018

1 reference

Targeting hypoxia cell signaling for cancer therapy

21 January 2018

1 reference

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

21 January 2018

1 reference

Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications

21 January 2018

1 reference

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

21 January 2018

1 reference

Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?

21 January 2018

1 reference

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

21 January 2018

1 reference

Management of hepatocellular carcinoma

21 January 2018

1 reference

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness

21 January 2018

1 reference

Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma.

21 January 2018

1 reference

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

21 January 2018

1 reference

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

21 January 2018

1 reference

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study

21 January 2018

1 reference

Genetics of hepatocellular tumors.

21 January 2018

1 reference

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.

21 January 2018

1 reference

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.

21 January 2018

1 reference

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

21 January 2018

1 reference

Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma

21 January 2018

1 reference

Experimental mouse models for hepatocellular carcinoma research

21 January 2018

1 reference

Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors

21 January 2018

1 reference

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

21 January 2018

1 reference

Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EGH.10.58

1 reference

23 August 2017

1 reference